Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer

The human epidermal growth factor receptor 2 (HER2) is amplified in approximately 20% of breast cancers, and HER2 receptor targeting therapy is associated with a significant improvement in disease-free and overall survival. In several clinical trials, the pathologic complete response (pCR) rate was...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Jin Hyuk, Jeon, Chang Wan, Kim, Young Ok, Jung, Sungui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
5750
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668516/
https://www.ncbi.nlm.nih.gov/pubmed/33181670
http://dx.doi.org/10.1097/MD.0000000000023053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668516/
https://www.ncbi.nlm.nih.gov/pubmed/33181670
http://dx.doi.org/10.1097/MD.0000000000023053

Ejemplares similares